216 related articles for article (PubMed ID: 27164718)
1. Fingolimod-associated PML in a patient with prior immunosuppression.
Gyang TV; Hamel J; Goodman AD; Gross RA; Samkoff L
Neurology; 2016 May; 86(19):1843-5. PubMed ID: 27164718
[No Abstract] [Full Text] [Related]
2. Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data.
Sinnecker T; Hadisurya J; Schneider-Hohendorf T; Schwab N; Wrede K; Gembruch O; Gold R; Hellwig K; Pilgram-Pastor S; Adams O; Albrecht P; Hartung HP; Aktas O; Kraemer M
BMC Neurol; 2019 Aug; 19(1):190. PubMed ID: 31399069
[TBL] [Abstract][Full Text] [Related]
3. Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML.
Fischer-Barnicol B; Oechtering J; Kuhle J; Lorscheider J; Kappos L; Derfuss T
Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33272956
[No Abstract] [Full Text] [Related]
4. Hypothyroidism in multiple sclerosis patient during fingolimod treatment.
Flores J; Rito Y; Torres G; Jung H; Treviño-Frenk I; Corona T
J Neurol Sci; 2015 Jan; 348(1-2):272-3. PubMed ID: 25491264
[No Abstract] [Full Text] [Related]
5. Comment on 'Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?' Maillart et al.
Tur C; Montalban X
Mult Scler; 2014 Apr; 20(4):510-1. PubMed ID: 24468818
[No Abstract] [Full Text] [Related]
6. Kaposi sarcoma in a fingolimod-treated patient with multiple sclerosis.
Walker S; Brew B
J Clin Neurosci; 2016 Sep; 31():217-8. PubMed ID: 27168454
[TBL] [Abstract][Full Text] [Related]
7. Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod.
Calvi A; De Riz M; Lecchi E; Pietroboni A; Ghezzi L; Scarioni M; Carandini T; Pellegrinelli A; Maurichi A; Galimberti D; Scarpini E
J Neurol Sci; 2017 Oct; 381():296-297. PubMed ID: 28991701
[No Abstract] [Full Text] [Related]
8. PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?
Lehmann-Horn K; Penkert H; Grein P; Leppmeier U; Teuber-Hanselmann S; Hemmer B; Berthele A
Neurology; 2016 Jul; 87(4):440-1. PubMed ID: 27343070
[No Abstract] [Full Text] [Related]
9. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
Ward MD; Jones DE; Goldman MD
Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342
[TBL] [Abstract][Full Text] [Related]
10. Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis.
Beadnall HN; Gill AJ; Riminton S; Barnett MH
Neurology; 2016 Dec; 87(24):2595-2597. PubMed ID: 27856777
[No Abstract] [Full Text] [Related]
11. Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis.
Christopher KL; Elner VM; Demirci H
Ophthalmic Plast Reconstr Surg; 2017; 33(3):e73-e75. PubMed ID: 27533512
[TBL] [Abstract][Full Text] [Related]
12. Ventricular arrhythmia in a male MS patient on fingolimod.
van Pesch V; Marchandise S; El Sankari S; Sindic C
Acta Neurol Belg; 2015 Mar; 115(1):77-9. PubMed ID: 24710722
[No Abstract] [Full Text] [Related]
13. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
Maillart E; Louapre C; Lubetzki C; Papeix C
Mult Scler; 2014 Apr; 20(4):505-9. PubMed ID: 24367037
[TBL] [Abstract][Full Text] [Related]
14. Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
Boudot de la Motte M; Louapre C; Bertrand A; Reach P; Lubetzki C; Papeix C; Maillart E
Mult Scler; 2017 Apr; 23(4):614-616. PubMed ID: 28273764
[TBL] [Abstract][Full Text] [Related]
15. Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
Peaureaux D; Pignolet B; Biotti D; Bucciarelli F; Gaina J; Bucur C; Clanet M; Martin-Blondel G; Brassat D
Mult Scler; 2015 Apr; 21(5):671-2. PubMed ID: 25305251
[No Abstract] [Full Text] [Related]
16. Fingolimod-associated macular oedema.
Jasani KM; Sharaf N; Rog D; Aslam T
BMJ Case Rep; 2017 Jun; 2017():. PubMed ID: 28619738
[No Abstract] [Full Text] [Related]
17. Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap?
Avasarala J; Jain S; Urrea-Mendoza E
J Clin Pharmacol; 2017 Nov; 57(11):1415-1418. PubMed ID: 28543950
[No Abstract] [Full Text] [Related]
18. Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis.
Sharim J; Tashjian R; Golzy N; Pouratian N
J Clin Neurosci; 2016 Aug; 30():166-168. PubMed ID: 26970935
[TBL] [Abstract][Full Text] [Related]
19. PML: The Dark Side of Immunotherapy in Multiple Sclerosis.
Warnke C; Olsson T; Hartung HP
Trends Pharmacol Sci; 2015 Dec; 36(12):799-801. PubMed ID: 26497099
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.
Tagawa A; Ogawa T; Tetsuka S; Otsuka M; Hashimoto R; Kato H; Ando K; Tanabe H
Mult Scler Relat Disord; 2016 Sep; 9():155-7. PubMed ID: 27645365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]